Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Rhea-AI Summary
BioArctic (NASDAQ Stockholm: B) will publish its fourth quarter report for October–December 2025 on 18 February 2026 at 08:00 a.m. CET. A presentation with CEO Gunilla Osswald and CFO Anders Martin-Löf will follow at 09:30 a.m. CET, including a Q&A, webcast and teleconference options.
Registration links, dial-in information, and archived webcast access are provided on the company's investor site. Contact details for investor relations are listed for follow-up.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Gold peers like WPM (+1.66%), FNV (+2.96%) and AU (+1.07%) also show gains, but scanner data does not flag a coordinated sector momentum move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 06 | Royalty sales update | Positive | +2.7% | Leqembi Q4 2025 sales drove higher SEK royalty versus prior year. |
| Feb 05 | Earnings results | Positive | -7.2% | Record Q4 and FY 2025 results with strong cash flow and production. |
| Feb 05 | Dividend and buybacks | Positive | -7.2% | Large Q4 dividend hike and substantial share repurchases with new policy. |
| Feb 05 | Board changes | Neutral | -7.2% | New board appointments and leadership changes linked to IPO planning. |
| Feb 04 | Clinical strategy shift | Neutral | -0.4% | Pipeline refocus of CS014 toward PH-ILD with Phase II plans for 2027. |
Recent history shows mixed alignment: positive commercial updates drew gains, while strong financial/dividend news coincided with notable share price declines.
Over recent months, news flow has spanned royalty growth, record financial results, capital returns and strategic changes. A Leqembi sales update on Feb 6, 2026 with higher royalties aligned with a +2.71% move. In contrast, full-year 2025 results and a higher dividend on Feb 5, 2026 coincided with a -7.16% reaction, as did board appointments the same day. Earlier, a clinical development shift at Cereno Scientific prompted only a modest move. Today’s scheduling of the Q4 2025 report fits into this ongoing cadence of earnings and strategic updates.
Market Pulse Summary
This announcement informs the market of BioArctic’s Q4 2025 report release on February 18, 2026 at 08:00 CET and a results presentation at 09:30 CET. It signals the next defined catalyst in the company’s calendar but contains no new financial metrics. Investors comparing this to recent history may note that prior royalty and earnings updates have drawn varied price reactions, underscoring the importance of the forthcoming numbers and guidance once disclosed.
AI-generated analysis. Not financial advice.
In conjunction with the report, BioArctic invites investors, analysts, and media to a presentation on February 18, at 09:30 a.m. CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the fourth quarter report, followed by a Q&A session.
If you wish to participate via webcast, please use the link below. You will be able to submit written questions during the webcast.
Webcast: https://bioarctic.events.inderes.com/q4-report-2025/register
If you wish to participate via teleconference, please register using the link below. After registering, you will receive phone numbers and a conference ID to access the conference. Questions can be asked verbally during the teleconference.
https://events.inderes.com/bioarctic/q4-report-2025/dial-in
The webcast will also be available on BioArctic's corporate website after the presentation. https://www.bioarctic.com/en/investors/financial-reports-and-presentations/
For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Tel: + 46 704 10 71 80
Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Tel: +46 76 013 86 08
This information was submitted for publication at 08:30 a.m. CET on February 11, 2026.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Invitation to presentation of BioArctic’s fourth quarter report for October â€" December 2025 |
View original content:https://www.prnewswire.com/news-releases/invitation-to-presentation-of-bioarctics-fourth-quarter-report-for-october--december-2025-on-february-18-at-9-30-am-cet-302684803.html
SOURCE BioArctic
FAQ
When will BioArctic (B) release its Q4 2025 report and where can I access it?
What time is the BioArctic (B) Q4 2025 presentation and who will present?
How can investors join BioArctic's Q4 2025 presentation webcast or teleconference?
Can I ask questions during BioArctic's Q4 2025 presentation and how?
Where will the BioArctic (B) Q4 2025 webcast be archived after the presentation?
